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Abstract: Metabolic bone disease is a frequent co-morbidity in newly diagnosed adults with 
celiac disease (CD), an autoimmune disorder triggered by the ingestion of dietary gluten. This 
systematic review of studies looked at the efficacy of the gluten-free diet, physical activity, 
nutrient supplementation, and bisphosphonates for low bone density treatment. Case control 
and cohort designs were identified from PubMed and other academic databases (from 1996 
to 2015) that observed newly diagnosed adults with CD for at least one year after diet 
treatment using the dual-energy x-ray absorptiometry (DXA) scan. Only 20 out of 207 studies 
met the inclusion criteria. Methodological quality was assessed using the Strengthening of the 
Reporting of Observational Studies in Epidemiology (STROBE) statement checklist.  
Gluten-free diet adherence resulted in partial recovery of bone density by one year in all studies, 
and full recovery by the fifth year. No treatment differences were observed between the  
gluten-free diet alone and diet plus bisphosphonates in one study. For malnourished patients, 
supplementation with vitamin D and calcium resulted in significant improvement. Evidence 
for the impact of physical activity on bone density was limited. Therapeutic strategies aimed 
at modifying lifestyle factors throughout the lifespan should be studied.  
Keywords: celiac disease; gluten; osteoporosis; diet; physical activity; bone density;  
nutrient deficiency 
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1. Introduction 
Celiac disease (CD) is triggered in genetically susceptible individuals by dietary gluten that results in 
intestinal damage and occurs in 1% of the population in Europe and the United States [1]. Approximately 
75% of newly diagnosed patients with celiac disease have low bone mineral density (BMD). And when 
matched by age and gender to a non-affected population, celiac patients have a 40% greater risk for bone 
fracture [2]. Even with a silent or extra-intestinal presentation such as dermatitis herpetiformis or dementia, 
low bone mass is frequently found [3–5]. One-third of newly diagnosed cases are over 60 years of age which 
coincides with a period of an increased risk of falls only worsened by the presence of co-morbidities [6,7]. 
Women with celiac disease have a much higher rate of fractures during the 10 year period prior to diagnosis 
and 5 years afterward [8]. The cumulative effects of gluten-induced inflammation, treatment delay, and 
malabsorption result in lower bone density and bone fragility. 
The most effective treatment for celiac disease and related co-morbidities, the gluten-free diet (GFD), 
is without dispute in the literature. Yet, improvements in BMD after treatment can take as long as two to 
five years after mucosal recovery [9–12] Nutritional deficiencies are common during the initial year of 
treatment for celiac disease, but little data exists on adult micronutrient status and bone mineral density in 
this population beyond calcium and vitamin D status [13–16]. 
The objective of this systematic review is to examine whether a GFD, alone or in combination with 
other interventions, leads to bone mineral recovery in newly diagnosed adults with celiac disease. A 
second objective is to identify gaps in the literature that would inform the design of future clinical trials 
and health intervention studies. 
2. Methods 
2.1. Criteria for Considering Studies for this Review 
The literature search was limited to English-language articles on untreated and treated adults with 
celiac disease observed for one year or more. Studies that were exclusively silent or asymptomatic were 
included if they were part of the sample due to their known bone mineral status. The types of studies 
considered were cohort, case-control, and randomized controlled designs. Case report and case series 
were excluded from the analysis. Studies that included co-morbid conditions, such as diabetes or primary 
hyperparathyroidism, were excluded. Randomized controlled trials and interventions that identified  
the dose, frequency, type of nutrition supplementation, and physical activity were sought. 
2.2. Search Strategy for Identification of Studies 
A keyword search was accomplished in PubMed (January 1996 to April 2015); Embase; CINAHL 
plus full text; EBSCO; Scopus; ProQuest Dissertations and Theses, and University of Connecticut library 
resources (HOMER). The MEDLINE search strategy keywords were “celiac disease” [MeSH]) AND 
(“bone mineral density” OR “osteoporosis” OR “bone density”) AND (“exercise” OR “physical 
activity”) AND (“nutrition” OR “gluten-free”) in publication title, abstract, or full-text. The inclusion 
criteria for this effort were studies with a focus on the treatment of newly diagnosed adults with celiac 
disease that reported the dependent variable as bone mineral density (BMD) as a dual-energy X-ray 
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absorptiometry (DXA) T-score at baseline and at the annual assessment. Treatment modalities sought 
included gluten-free diet, physical activity, or vitamin and mineral supplementation. Case studies and 
papers that did not report DXA data at baseline were excluded.  
Key article reference lists were hand searched from the Cochrane database of systematic reviews, 
meta-analyses, and review articles, as well as papers in (Bone, Gut, Osteoporosis International, and 
American Journal of Gastroenterology). Finally, journal review articles, and meta-analyses for non-celiac 
studies of low BMD were reviewed. 
2.3. Quality Assessments 
The clinical trials meeting the criteria are listed in Table 1. Methodological quality was assessed using 
the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology Statement) 
recommendations using separate checklists for conference abstracts, case control studies, cohort studies, 
and cross-sectional studies [17]. The use of a qualitative assessment using a percentage system to 
categorize the studies as proposed by other authors proved to be unreasonable because of the age of some 
of the papers, published years before the STROBE recommendations [18]. The final system used was a 
combination of STROBE (50%–80% fulfilled) and whether missing items left the reader questioning 
eligibility criteria or bias in the results reported. After 2008, most of the papers fell into the “A”  
quality category. 
2.4. Overview of Studies 
Three categories of study were identified: GFD; GFD and nutritional supplement; GFD and 
bisphosphonates; and a combination of GFD, supplement and exercise. The outcome measures in 
selected articles included: DXA (femoral neck, trochanter and lumbar spine), ligand of receptor activator 
of NFκB (RANKL) /osteoprotegerin (OPG) ratio, adherence to a GFD, and physical activity level. The 
clinical trials meeting the criteria are listed in Table 1. 
3. Results 
After the initial screening of articles and abstracts from the initial search strategy, a total of 180 articles 
were retrieved. The systematic process yielded 20 reports (Figure 1). During the period of this review 
there was an evolution in diagnosis and classification of CD with greater acceptance of serology test 
results for screening and monitoring in adults, combined with biopsy for diagnosis [19–21]. These 
developments made study comparisons more difficult because of the clinical heterogeneity between 
subjects with little or no villous atrophy.  
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Table 1. Studies meeting search criteria. 
Author Publication Year 
Summary 
Title Design Treatment Participants Results Quality 
Corazza (1996) [22] 
Reversal of osteopenia with diet in adult 
coeliac disease 
Prospective,  
case-control  
GFD 
Gender (M/F) Classical CD 9/10,  
Mdn age = 26.5 years, Subclinical 
untreated 11/14, Mdn age = 28.5 years, 
Control 13/15 (Mdn age = 28) 
GFD normalizes BMD in subclinical, but not 
classical CD. 
B 
Valdimarsson (1996) [23] 
Influence of pattern of clinical 
presentation and of gluten-free diet on 
bone mass and metabolism in adult 
coeliac disease 
Prospective,  
case-control 
GFD 
n = 63, Age range = 17–79 years,  
M/F = 28/35 
After one year taking a GFD bone mineral 
density increased at all sites (p < 0.01). Seven 
patients with dermatitis herpetiformis had 
normal BMD, vitamin D & PTH status 
B 
McFarlane (1996) [24] 
Effect of a gluten free diet on osteopenia 
in adults with newly diagnosed coeliac 
disease 
Prospective, cohort GFD 
n = 21 M/F = 14/7, Mean age = 49.7 
years (31.0 to 66.1) 
Almost half of subjects had osteoporosis. After 
1 year of treatment there was significant 
improvement in BMD 
B 
Ciacci (1997) [25] 
Effects of dietary treatment on bone 
mineral density in adults with celiac 
disease: factors predicting response 
Prospective,  
case-control 
GFD & calcium 
Gender (M/F) 11/30 n = 41,  
M/F = 11/30, Mean age = 34.3 
Mean BMD (g cm−2) significantly improved by 
one year after GFD treatment in most, but not 
all subjects. 
B 
Mautalen (1997) [26] 
Effect of treatment on bone mass, 
mineral metabolism, and body 
composition in untreated celiac disease 
patients. 
Prospective, RCT 
GFD or GFD plus calcium 
(1 g day−1) & vitamin D 
(32,000 IU week−1) 
n = 41, M/F = 11/30, Mean age = 34.3 
years 
Mean BMD (g cm−2) significantly improved by 
one year in most but not all subjects. 
B 
Kemppainen (1999) [27] 
Bone recovery after a gluten-free diet: a 
5-year follow-up study 
Prospective, cohort GFD 
n = 28 newly diagnosed CD patients  
(9 men, 19 women) recruited from 1990 
to 1991. 6 patients withdrew. Women 
Age = 44.1 ± 13.6 and Men Age = 48.6 
± 12.3 Compliance with the GFD was 
good: 96% at 1 year and 82% at 5 years. 
Bone disease “cured” by 5 years; with most of 
improvement in the first 12 months. 
A 
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Table 1. Cont. 
Author Publication Year 
Summary 
Title Design Treatment Participants Results Quality 
Valdimarsson (1999) [28] 
Low circulating insulin-like growth 
factor 1 in coeliac disease and its 
relation to bone mineral density 
Prospective,  
case-control, 
longitudinal 
GFD 
n = 29 CD, Mean age = 41 years, 
(range 21–66), M/F 8/21, n = 29 
controls, age and gender matched 
BMD and circulating IGF-1 levels are low in 
adults with untreated CD. 
A 
Sategna-Guidetti (2000) [29] 
The effects of 1-year gluten 
withdrawal on bone mass, bone 
metabolism and nutritional status in 
newly-diagnosed adult coeliac 
disease patients 
Prospective, cohort GFD 
n = 86 newly diagnosed CD,  
M/F = 22/64, mean age M/F = 29/29 
GFD leads to significant increase in BMD and 
IGF-1 levels in postmenopausal women and 
in patients with incomplete mucosal recovery. 
Folic acid, albumin and pre-albumin serum 
levels low for those with incomplete recovery. 
A 
Taranta (2004) [30] 
Imbalance of osteoclastogenesis-
regulating factors in patients with 
celiac disease 
Prospective,  
case-control, 
longitudinal 
GFD 
n = 25 treated, n = 17 untreated,  
n = 17 controls, Treated group  
mean age = 35.7 ± 7.9 years, 
Untreated mean age = 43 ± 9.9 
Results suggest that bone loss in CD caused 
by a cytokine imbalance directly affecting 
osteoclastogenesis. RANKL/osteoprotegerin 
ratio was increased in patients not on the GFD. 
A 
Bucci (2008) [31] 
PO.7 Physical activity does not 
influence bone mass density in 
celiac adult patients 
Prospective cohort Unrestricted and GFD 
n = 57 adults, age range = 18–45,  
CD enrolled, 38 completed the study 
protocol after a 24 months of GFD. 
High rate of dropout (33%). 
GFD induced increase of BMD at femur 
independently of the amount of reported 
physical activity, but difference was not 
significant from baseline to follow-up in the 
low BMD group. PA was did not differ from 
baseline at 24 months. 
B 
Kurppa (2010) [32] 
Gastrointestinal symptoms, quality 
of life and bone mineral density in 
mild enteropathic coeliac disease: A 
prospective clinical trial. 
Prospective,  
cohort study 
GFD 
n = 27 (mild enteropathy ),mean age 
(16–70); n = 46 (celiac), mean age 46 
(16–70); BMD measured in n = 19 
(normal villi), n = 39 (villus atrophy); 
n = 110 non-celiac controls mean age 
49 (24–87) 
Osteoporosis or osteopenia was detected in 
58% of subjects in the mild enteropathy group 
and there was a trend towards improved bone 
mineral density after the treatment. 
B 
  
 
Nutrients 2015, 7 3352 
 
Table 1. Cont. 
Author Publication Year 
Summary 
Title Design Treatment Participants Results Quality 
Papamichael (2010) [33] 
S2044 effect of a gluten free diet on 
bone mineral density in patients 
with celiac disease. 
Prospective cohort 
GFD/Vitamin D  
and calcium 
n = 22 CD patients, M/F = 7/15,  
mean age = 33 (21–69) years 
Women diagnosed with CD because of overt 
malabsorption had osteoporosis despite 
supplementation with calcium and vitamin D. 
At baseline 10 female and all male patients had 
osteopenia. After 1 year 3 osteoporotic women 
had osteopenia, while the remaining 19 
patients had a normal BMD. 
B 
Duerksen & Leslie (2011) [34] 
Longitudinal evaluation of bone 
mineral density and body 
composition in patients with 
positive celiac serology 
Retrospective 
cohort, database 
GFD 
Age > 40 years at baseline and testing for 
CD within 6 mo of baseline DXA test Groups: 
37 (seropositive)/214 (controls) 
Increase in BMD, BMI, and abdominal fat on 
GFD. Seropositive versus seronegative 
individuals had greater increases in mean spine 
BMD (4.6%/year vs. 0.7% spine, p < 0.0001), 
hip BMD (3.0%/year vs. 0.2% year−1 hip,  
p < 0.0001). 
A 
Vilppula (2011) [35] 
Clinical benefit of gluten-free diet 
in screen-detected older celiac 
disease patients. 
Prospective,  
cohort study 
GFD 
n = 35, Median age = 61 years  
(range 52–76), M/F = 15/20 
Screen detected older celiac may suffer from 
subclinical malnutrition, GI symptoms or bone 
disease. Significant difference between pre & 
post-treatment femoral and lumbar spine Z 
scores. 
A 
Casella (2012) [36] 
Celiac disease in elderly adults: 
clinical, serological, and 
histological characteristics and the 
effect of a gluten-free diet 
Retrospective, 
cohorts grouped  
by age 
GFD 
M: n = 16(A), n = 306(B) F: n = 43(A),  
n = 860(B) Mean Age at diagnosis, µ ± SD: 
70.1 ± 4.3 (65–83 years), 35.2 ± 10.6  
(18–64 years) 
Prevalence of osteoporosis was 67% in older 
and 14% in younger male participants and 70% 
in older and 9% in younger female participants 
(p < 0.001). Lumbar-sacral and femoral  
T-scores increased significantly during GFD in 
pooled results of 48 older and younger 
participants studied before and during GFD. 
A 
 
  
 
Nutrients 2015, 7 3353 
 
Table 1. Cont. 
Author Publication Year 
Summary 
Title Design Treatment Participants Results Quality 
Passananti (2012) [37] 
Bone mass in women with celiac 
disease: role of exercise and gluten-
free diet 
Prospective, 
cohort, 
longitudinal 
GFD 
48 women of 2-year FU group  
(Mean age = 35.1 ± 8.7 years) and  
47 women of 5-year FU group  
(Mean age = 35.1 ± 11.3 years) 
Improvement in BMD on GFD was 
significant after 2 years; physical activity was 
frequently low. No significant relationship 
was observed between the BMD for 2-year 
FU and 5-year FU and level of physical 
activity at diagnosis (p > 0.05) for the lumbar 
spine and for the proximal femur). 
B 
Szymczak (2012) [38] 
Low bone mineral density in adult 
patients with coeliac disease 
Prospective,  
case-control, 
longitudinal 
GFD plus calcium & 
alfacalcidol (vitamin D) 
n = 19 treated, n = 16 untreated and  
36 controls, second study of 
supplementation and GFD  
n = 35 CD group M/F = 6/29,  
Mean age 41.5 ± 13.6 years 
Adult CD subjects treated with GFD for  
one year. They were deficient in calcium, 
vitamin D, and had lower BMD than controls. 
Then treated and untreated subjects given diet 
and supplements for one year. GFD compliant 
subjects taking supplements had a 35% 
increase in BMD, but gain was less in  
non-adherent subjects. 
B 
Kumar (2013) [39] 
Effect of zoledronic acid on bone 
mineral density in patients of celiac 
disease: a prospective, randomized, 
pilot study 
Randomized, 
prospective 
GFD group A; and GFD & 4 
mg zoledronic acid, calcium 
(1000 mg) and 
cholecalciferol (0.6 million 
units) if serum vitamin D 
was low, group B 
n = 13 (11 completes), and n = 15 
M/F = 7/6 and 7/8, 
Mean age 28.2 ± 12.8 years; 25.3 ± 9.1 
years 
Significant improvement in clinical, 
biochemical parameters in both groups; GFD 
with Zoledronic acid was not found to be 
better than GFD alone after one year. 
A 
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Table 1. Cont. 
Author Publication Year 
Summary 
Title Design Treatment Participants Results Quality 
Kurppa (2014) [40] Benefits of a gluten-free diet for 
asymptomatic patients with 
serologic markers of celiac disease. 
Prospective,  
cohort, RCT 
Unrestricted and GFD n = 40 randomized to GFD group or 
unrestricted group, n = 20 (M/F = 15/5), 
n = 20 (11/9), Mean age: 42 (21–74) 
years GFD, Mean age: 42 (21–74) 
years, unrestricted diet 
There were no differences between groups in 
laboratory test results, BMD (lumbar spine 
and femur neck), or body composition. Most 
measured parameters (GI symptoms, psych 
well-being, and SF-36 QOL) improved when 
patients in the gluten-containing diet group 
were placed on GFDs. 
A 
Pantaleoni (2014) [4] 
 
Bone mineral density at diagnosis 
of celiac disease and after 1 year of 
gluten-free diet. 
Prospective 
cohort 
GFD (M/F) n = 146/23 Mean age:  
38.9 ± 12.6 years,  
pre/post-menopausal = 104/42 
Stratification of patients according to sex and 
age showed a higher prevalence of low bone 
mineral density in men older than 30 years 
and in women of all ages. GFD led to  
a significant improvement in lumbar spine 
and femoral neck mean T-score value 
A 
CD: celiac disease; F: female, M: male; BMD: bone mineral density; GFD: gluten-free diet; PA: physical activity; DXA: dual-energy X-ray absorptiometry; BMI: body 
mass index; FU: follow-up; SF-36 QOL: standard quality of life index; yr.: year; Quality assessment was performed by the author according to STROBE recommendations. 
RANKL: receptor activator of nuclear factor-κB ligand; PTH: parathyroid hormone; IGF-1: Insulin-like growth factor 1; PA: Physical activity. 
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Various tests are used to measure bone density, including the DXA, quantitative computed 
tomography (QTC), photon absorptiometry, and ultrasound. Adult bone mineral loss is categorized into 
osteopenia and osteoporosis. The World Health Organization (WHO) has established DXA as the best 
densitometry technique for the measurement of bone density in postmenopausal women, but the 
sensitivity of the DXA is lower compared to QTC in individuals with celiac disease [41]. A T-score between 
−1 and −2.5 and ≤2.5 indicates bone mineral loss with a greater than average risk of fracture [12]. Multiple 
risk factors and the results of the DXA scan are good predictors of relative fracture risk, and prediction 
is enhanced when co-morbidities, such as celiac disease, are added to the FRAX (WHO Fracture Risk 
Assessment Tool) index [42].  
3.1. Diet Therapy 
The studies reviewed that reported a dietary compliance measure demonstrated that adherence to the 
GFD has a positive effect on bone mineral density [4,36,38,43]. The greatest diet treatment gain occurs 
in the first year of in longitudinal studies that followed individuals for more than 12 months [27,34,37]. 
But full recovery for adults was mainly achieved after 5 years [27]. Newly diagnosed older adults benefit 
from the GFD with significant gains in femoral and lumbar spine being reported in the first year of 
treatment [35,36]. Malabsorption associated malnutrition delayed restoration of BMD in a vitamin D 
and calcium supplemented high risk group, while less nutritionally compromised individuals in the same 
study progressed from osteoporosis to osteopenia by one year of treatment [33]. Bone turnover markers 
Interleukin-18 (IL-18), Interleukin-6 (IL-6), and N-terminal telopeptide of procollagen type I were 
measured in treated (n = 25), untreated individuals (n = 17), and controls (n = 21) [30]. The GFD group 
had reduced levels of IL-18 and a lower RANKL/osteoprotegerin (OPG) ratio compared to untreated 
subjects, while the N-terminal telopeptide of procollagen type I was comparable to controls. Another 
study looked at the regulation of osteoclastogenesis and bone turnover in celiac disease in a cohort study 
of healthy premenopausal female subjects and diet compliant individuals with celiac disease who had no 
evidence of hypoparathyroidism [44]. The authors reported that the OPG/RANKL ratio was significantly 
lower in CD patients than in controls (14.8 ± 6.9 vs. 19.4 ± 9.2; p < 0.05). 
Overall, the studies have shown that a GFD for the majority of patients is an effective therapy for 
long-term bone mineral recovery. The use of intermediate measures such as BMD, quality of life, and 
bone turnover, is more practical than fracture reduction estimates because these studies followed patients 
for one to five years. The incidence of fractures in a group of diet compliant participants (n = 265,  
M/F = 422/223) before and 5 years after diagnosis was compared to a cohort of patients with functional 
gastrointestinal disorders (n = 530, M/F = 84/446) [45]. The incidence of fractures declined after 
treatment (Incidence Rate (IR) = −1.22 events per 1000 patients year−1) and Health Risk (HR) of fracture 
was comparable to controls (HR: 1.28, 95% CI: 0.74–2.21, p = ns), thus confirming the long-term benefit 
of the GFD. 
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Figure 1. Selection process for studies included in the systematic review. 
3.1.1. GFD and Nutrient Supplementation 
The review identified 3 articles that addressed the treatment effects of vitamin and mineral 
supplementation on BMD [25,26,33]. The approach of Ciacci, et al. was a constant dietary calcium level 
of 1250 mg daily with diet alone or the addition of a supplement for those who were intolerant to  
lactose [25]. There was no significant change in vitamin D, urinary calcium increased, and a significant 
increase in BMD in the lumbar spine, femoral neck, and Ward’s triangle in this study. Non-responders 
were more likely to be older and menopausal. Mautalen and associates randomized participants to  
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a gluten-free diet condition (n = 7) or diet plus calcium (1.0 g day−1) and vitamin D (32,000 IU week−1)  
(n = 7) [26]. This trial’s results were compromised by non-compliance. Adherent subjects had significant 
gains in BMD compared to patients that with frequent lapses, and improvement favored the axial compared 
to the peripheral skeleton. Lastly, Papamichael, et al. observed serum 25(OH)D3, parathyroid  
hormone (PTH), and calcium before and after treatment [33]. Only women with severe malabsorption 
were given supplements, the rest of the study group relied on the GFD and sunshine. In summary, the 
effect of supplementation depends on the disease severity at diagnosis and environmental exposure to 
UV radiation. The BMD of the majority of patients improved significantly to adequate vitamin D and 
calcium in the first year. 
Satenga-Guidetti, et al. evaluated the pre- and post-treatment nutrient status of subjects (n = 86) on  
a GFD with no supplementation with serum folate, 25OH-D, hemoglobin, transferrin, and albumin 
measurement, as well as urinary calcium [29]. The researchers observed after a one-year follow-up that 
34% of 86 newly diagnosed CD patients had a normal bone mineral density, while 40% had osteopenia 
and 26% osteoporosis with dietary treatment. There were no differences between gender in bone metabolism 
markers or most nutritional indices. The only difference was between pre- and post-menopausal women, 
where BMD and several bone metabolic markers were significantly different. This is in contrast to 
another study where reduced BMD was found after complete healing of duodenal lesions in one half of 
their patient sample [46]. The researchers concluded that additional measures beyond dietary compliance 
and counseling should be taken into account in order to increase BMD. 
Treatment failure may actually be the result of a highly processed GFD as it is associated with small 
bowel bacterial overgrowth (SIBO) [47]. A highly processed GFD has been shown to alter the gut 
microbiome and increase GI symptoms which leads to an increased permeability of the epithelial barrier 
in patients with CD [48–50]. The health of the gut microbiota and the symptoms related to SIBO impact 
normalization of bone metabolism. The GFD does not reduce the risk of serious co-morbidities such as 
small bowel adenocarcinoma, Enteropathy-Associated T-cell Lymphoma (EATL), abortions, 
myocardial infarction, colonic adenocarcinoma, gastric MALT-lymphoma, ulcerative jejuno-ileitis, 
Cholangitis, severe non-alcoholicsteato-hepatitis, and autoimmune thrombocytopenia [51]. 
Nutritional status at time of diagnosis, age, menopausal status, environment, and dietary compliance 
moderate the effect of dietary supplements on BMD. Controversy exists regarding the amount of 
supplementation required to reverse malnutrition for key nutrients. A large clinical trial comparing the 
constant vitamin D and calcium dietary approach to a GFD without supplementation is needed. Because 
the maintenance of serum vitamin D is improved in the presence of adequate calcium intakes and high 
levels of physical activity, the study should collect direct measures of total UV radiation exposure and 
physical activity [52]. 
3.1.2. GFD and Bisphosphonates 
The use of hormone replacement therapy or bisphosphonates, has been shown in healthy pre- and 
post-menopausal women to be effective in restoring bone mass; and the data suggests that combining 
these therapies with weight-bearing exercise may have additive effects [53,54]. A small pilot study  
(n = 28) treating CD patients with either GFD and zoledronic acid, or a calcium and cholecalciferol 
supplemented GFD reported that there were no significant difference in effectiveness [39]. Replication 
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of this study with a larger sample size that includes older adults may be more representative of the adult 
CD population.  
3.1.3. GFD and Physical Activity 
Few researchers have studied the effect of physical activity on bone density in this population. 
Passananti and associates studied two groups of women (20–60 years), and compared baseline measures 
for the International Physical Activity Questionnaire (IPAQ), fatigue visual analogue scale (VAS), 
dietary compliance, gastrointestinal symptoms, serum vitamin D, anti-transglutaminase antibodies  
(U mL−1), and BMD in 2 or 5 year follow-up cohorts [37]. Women who were taking oral contraceptives 
or hormone replacement therapy were excluded. A total of 110 participants were enrolled into the study, 
but 15 were either lost to follow-up or did not adhere to the GFD. The final sample size of the  
two cohorts were n = 48, n = 47, for the 2 and 5 year follow-up cohorts respectively. BMD measurements 
were taken at the right femur and lumbar spine. Chi-square tests were used for categorical data and 
ANOVA for continuous measures. Baseline and follow-up (FU) BMD was analyzed by two-sample and 
pairwise t-tests with a confidence interval set at 95%. Health measures also included BMI, small intestine 
pathology using Marsh categories for lesion comparisons and age of menarche and menopause. In the 
2-year FU group 53.7% of participants reported low physical activity, and 10.6% were highly active 
(IPAQ = 3). Compared to baseline fatigue in this group, there was no statistical difference. The 5-year 
FU group was more active, with 46.3% reporting low levels and 14.6% highly active. Yet, the active 
subjects in in this group were more likely to report fatigue (p = 0.039 post hoc). The mean IPAQ score 
for both groups were not significantly different (1.60 ± 0.67 vs. 1.87 ± 0.88; p > 0.05). There was no 
significant difference between groups at FU for BMD and no relationship between BMD and intensity 
of Physical activity (PA) (p > 0.05 at the lumbar spine and proximal femur). The researchers concluded 
that physical activity has a minor role in supporting the bone mineral recovery in celiac patients. It is 
important to note that the study participants had normal vitamin D levels, but did not meet their dietary 
needs for calcium. 
Di Stefano (2000) observed lifestyle factors in untreated patients with CD and BMD [55]. The 
participants (n = 39) were drawn from a consecutive patient pool with a spectrum of gluten-sensitive 
disorders: classical celiac, herpetiformis dermatitis, subclinical, or refractory (non-responsive) sprue. 
The independent variables were gender, smoking status, symptom severity, symptom duration,  
sunlight exposure, and level of physical activity. PA level was determined by self-report of occupational, 
recreational (cycling and brisk walking), and activities of daily living on a 0–4 scale of frequency [56]. 
Predictors of BMD were gender, malnutrition, severity, and PA. Symptom severity predicted low BMD 
in lumbar and femoral neck (−2.5 ± 0.8, p < 0.001). PA was correlated with BMD at the lumbar  
(r = 0.57, p < 0.004) and femoral (r = −0.71, p < 0.004); and bone mineral content (BMC) was correlated 
with lumbar BMC (r = 0.59, p < 0.001) and femoral BMC (r = 0.58, p < 0.001). 
Studies concur that fatigue and celiac symptoms impact the frequency and intensity of exercise. The 
outcome measures, whether biochemical or radiologic, do not take muscle strength or flexibility  
into account. No direct measure of fitness level or every-day movement has been published. Aside from 
a study by Gonzalez et al. [57], few papers have identified overall body composition changes in spite of 
observations that treatment results in obesity in some patients [58,59]. In the elderly the impact of 
exercise on biochemical pathways involved in bone remodeling, such as receptor activator of nuclear 
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factor-κB (RANK) /RANKL/OPG, is positive and particularly responsive to specific types of exercise 
(e.g., high or low impact exercise and resistance training) [60]. It has been observed that individuals with 
CD have an altered osteoprotegerin/RANKL ratio, which may also predispose patients to cardiovascular 
disease [44,61] Future health intervention research in celiac disease should focus on improving wellness, 
strength, and functional capacity in this population. 
A randomized, double-blinded vs. placebo parallel study of the effectiveness of L-carnitine on fatigue 
in patients with celiac disease [62]. Participants were given a placebo or 2 g L-carnitine daily  
for 180 days. L-carnitine plays an important role in muscle contraction and energy production. The 
experimental group experienced an increase in organic cation transporter 2 (OCTN2), a sodium-dependent 
transporter for carnitine that facilitates carnitine absorption, as well as amines, some vitamins. The  
L-carnitine treatment group reported significant improvement in fatigue, as evaluated by the VAS scale. 
The rise in OCTN2 might explain this change. Ultimately, low levels of physical activity in persons with 
CD may be improved through L-carnitine treatment, which may aid in stimulation of bone  
mineral deposition. 
The specific type of exercise may be a critical factor for improving bone health. Marques and 
associates studied the effect of resistance and moderate-impact aerobics training protocols on proximal 
femur BMD, muscle strength, balance, body composition, serum OPG, and RANKL levels in older 
women (n = 71). After eight months of the intervention, only the resistance training group experienced 
positive changes in BMD and muscle strength [63]. Both protocols had significant effects on functional 
balance control, a key factor in fall prevention. A later study by this author observed the effect of combined 
impact training for balance and lower-extremity muscle strength in men and women; the researchers 
reported improvement in dynamic balance (6.4%), muscle strength (11.0%) and trochanter (0.7%), 
intertrochanter (0.7%), total hip (0.6%), and lumbar spine BMD (1.7%), while osteocalcin, OPG and 
RANKL levels remained unchanged [64]. Exercise performed with adequate dose and intensity addresses 
multiple risk factors for osteoporosis and fractures. Further research on celiac disease lifestyle intervention 
should begin with known barriers to PA and motivational therapies in other populations [65]. 
3.1.4. Nutritional Deficiencies, Dietary Sodium, Dysbiosis, and Inflammation 
Folate supplementation is an effective treatment for elevated homocysteine in CD [66]. B12 and iron 
deficiency is a common symptom in untreated CD and in one study it was discovered in 41% of 
participants [67]. Dahele and Ghosh reported that after oral and parenteral administration of B12, all 
patients (n = 39) had normal serum levels of B12 at one year follow-up. A new role for B12 in bone 
health has been demonstrated in a mouse model of B12 deficiency demonstrating that deficiency impairs 
taurine synthesis and enhances Growth hormone-dependent IGF-1 synthesis in the liver; this subsequently 
increases osteoblast function (Figure 1) [68]. Research in humans should focus on reevaluating  
vitamin B12 requirements in CD to determine its role in bone remineralization. 
Intestinal microbiota has been implicated in the development of CD which may not be corrected  
after treatment. Due to the low level of phylum Bacteroides and abundance of Firmicutes in the stools 
of people with CD, this imbalance has a pro-inflammatory effect by increasing IL-10 cytokine [69]. The 
GFD did not normalize gut bacteria in one two-year follow-up study of children with CD, and has been 
shown to induce dysbiosis in healthy adults fed a gluten-free diet for one month [50,70]. Vitamin D 
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metabolite 25(OH)2D3 has been shown in one vitro study to prime dendritic cells to induce regulatory T 
(Treg) cells [71]. In that study, the results showed that Dermal dendritic cell-derived IL-10 induce  
IL-10+ TR1 cells. Gut microbiota also affects T cell differentiation and host susceptibility to 
autoimmune disease [72]. Bifidobacterium genus is low in the stools of celiac patients on a GFD 
compared to healthy controls consuming a regular diet. This genus has been shown to protect against 
inflammation and mucosal damage caused by gliadin peptides in vitro [73]. 
A change in diet can bring about long-term improvement in chronic inflammation and malabsorption 
of nutrients due to alterations in the gut microbiome [74]. Enhanced barrier function due to diet and 
physical activity was shown in a study of professional elite rugby players eating a diet high in  
whey protein, fruits, and vegetables during training camp [75]. The DNA from fecal samples showed a 
rich diversity of organism such as phylum Firmicutes, genus Akkermansia, and fewer Bacteroides than 
in two less active controls groups comprised of normal weight and obese individuals. 
The conclusion of a multivariate analysis of factors predicting recovery in 30 women and 11 men w 
with CD as that gender (women), pretreatment age, and pretreatment BMD independently predict  
bone mineralization, especially in the lumbar spine [25]. The regression coefficient for lumbar spine 
BMD (+0.060 to +0.160 g cm−2) did not overlap the 95% confidence interval. The authors identified in 
their discussion that vitamin D3 supplementation may be an important factor that was not addressed in  
their study. In a double blind placebo controlled study, Fickling and associates (2001) administered 300,000 
units of choiecalciferol (vitamin D) by intramuscular injection or saline placebo to newly diagnosed CD  
patients [76]. Data was collected at 6, 12, and 24 months. Both groups saw improvements in BMD, but 
no significant difference was found between groups. 
A case report of a woman with severe bone mineral loss illustrates the need for individualized 
treatment of CD [14]. A 37-year-old, sedentary woman diagnosed with CD initially had a low BMD  
and was prescribed calcium (1000 mg day−1) and vitamin D (400 IU day−1). After one year a Registered 
Dietitian-Nutritionist verified diet compliance, serum vitamin D remained low (33 nmol L−1), and the dose 
was subsequently increased to 1000 IU day−1. After an 81% increase in the spine and 60% change in the hip 
at year 3, her bone mass plateaued by year 4. This demonstrates the need to evaluate lifestyle, nutrition, and 
bone status throughout treatment. 
A 10-year study of individuals with CD reported that more than half suffered from vitamin 
deficiencies in folate, B12 and B6, as evidenced by elevated homocysteine levels, low plasma folate, 
and B6 [77]. In a Dutch study of newly diagnosed adults (n = 80), researchers observed deficiencies in 
vitamin A, B6, folic acid, B12, and zinc in 67% of participants [78]. B12 and iron deficiency are common in 
untreated CD and in one study it was discovered in 41% of participants [67]. Dahele and Ghosh reported that 
after oral and parenteral administration of B12, all patients (n = 39) had normal serum levels of B12 at one 
year follow-up [67]. A new role for B12 in bone health has been shown in a mouse model of B12 deficiency 
demonstrating that deficiency impairs taurine synthesis and enhances growth hormone-dependent IGF-1 
synthesis in the liver; this subsequently increases osteoblast function [68]. Research in humans should focus 
on reevaluating vitamin B12 requirements in celiac disease to determine its role in bone remineralization. 
  
 
Nutrients 2015, 7 3361 
 
4. Discussion 
Our understanding of bone mineral metabolism and the impact of diet and exercise in the treatment 
of bone mineral loss for people with celiac disease is incomplete. For this review, the author identified 
published works and most of these were small, non-randomised clinical trials. Because most participants 
were recruited from University hospitals and specialty treatment centers, the results may be subject to 
sampling bias. In spite of an exhaustive search only two studies were found using randomised control, 
and these did not use an intention-to-treat analysis in spite of subject attrition. Studies also lacked 
uniformity in dietary intake and compliance assessment measures. It is critical to develop a database of 
individual raw data from studies on bone density and celiac disease so that a meta-analysis of individual 
participant data can be published [79]. This type of analysis can differentiate treatment effects for  
different sub-groups, such as non-responders. The incidence of CD continues to rise in all ages groups, 
creating need for better management of low BMD in adults and elderly [80]. 
Nutrient malabsorption due to chronic inflammation and villus atrophy are thought to be the major 
causes of low BMD (Figure 2). In bone, calcium is regulated by parathyroid hormone (PTH),  
1,25-dihydroxyvitamin D (Vitamin D3), and calcitonin [81]. Hyperparathyroidism is common in 
untreated celiac disease and is characterized by high bone turnover and cortical bone loss [82].  
In addition, alterations in gallbladder function, exocrine pancreatic insufficiency, and gut permeability 
reduce the absorption of essential nutrients [83]. BMD is directly related to the extent of villus atrophy 
which results in malabsorption of calcium, iron, vitamin D, and folic acid [84]. Even after long after the 
initiation of diet treatment calcium absorption may be reduced [85]. When administered with vitamin D, 
Vitamin K has been shown to increase BMD in osteoporosis and reduce fracture rates due to its role in 
calcium balance [86].  
Bone is dynamic tissue that is continuously going through resorption and absorption of calcium from 
blood to bone in a process called remodeling (Figure 3). The loss of bone density in CD is caused by  
an imbalance in osteoclastogenesis and osteoblast activity as reported from a study on newly diagnosed 
patients compared to individuals on a GFD [30]. The authors reported that proinflammatory factors,  
N-terminal telopeptide of procollagen type I and IL-6, were higher in the untreated CD group, thus 
suggesting that bone-turnover regulating factors contributed to the reduced bone mass. Other 
inflammatory factors involved in the pathogenesis of bone metabolism are osteoprotegerin (OPG), a 
member of the tumor necrosis factor receptor family, and RANKL. RANKL is a cytokine that stimulates 
osteoclast formation and activation in bone, while OPG acts as a decoy receptor for RANKL, thereby 
controlling its function. The OPG/RANKL ratio was significantly lower in CD patients in a controlled study 
of premenopausal women than age matched controls, and the OPG/RANKL ratio was correlated with loss 
of BMD at the spine [44]. Demographic and lifestyle factors such as age, gender, eating disorders, 
alcohol abuse, low physical activity, and smoking are also associated with low BMD in CD [55,80,87]. 
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5. Conclusions 
The most important behavior impacting bone density in celiac disease is diet adherence. The 
psychological determinants of GFD adherence, such as self-discipline, values, depression, anxiety, and 
presence of other food intolerances may have an effect on bone rehabilitation [88]. Patients who struggle 
with personality and psychological barriers to diet compliance may benefit from motivational interviewing 
techniques early in treatment [89]. Adults diagnosed with celiac disease may have malabsorption of  
long-standing, therefore may benefit from iron, folate, B12, vitamin D3, vitamin K, calcium, magnesium 
and docosahexaenoic acid (DHA) therapy [66,77,90]. The nutrient density shortcomings of the  
gluten-free diet call for the early and individualized services of a registered dietitian-nutritionist with 
celiac disease expertise in both medical nutrition therapy and lifestyle coaching [91]. 
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